The Journal of Urology
Volume 180, Issue 5 , Pages 1993-2004 , November 2008

Best Practice Statement on Cryosurgery for the Treatment of Localized Prostate Cancer

  • Richard J. Babaian (Chair)

      Affiliations

    • Financial interest and/or other relationship with Endocare and Gen-Probe.
    • ,
  • Bryan Donnelly (Facilitator)

      Affiliations

    • Financial interest and/or other relationship with Endocare.
    • ,
  • Duke Bahn
    • ,
  • John G. Baust

      Affiliations

    • Financial interest and/or other relationship with Galil Medical.
    • ,
  • Martin Dineen

      Affiliations

    • Financial interest and/or other relationship with Endocare, Abbeymoor Medical Inc., Mentor, GlaxoSmithKline, AstraZeneca, GTX, National Cancer Institute, Amgen, Oakwood Pharmaceuticals, Duramed, Ce3-ION, Tap Pharmaceuticals, Wilex, EDAP Pharmaceuticals, AngioDynamic, Inc., Panacea, Aeterna Zentaris, OrthoMcNeil/Johnson & Johnson and Pfizer.
    • ,
  • David Ellis

      Affiliations

    • Financial interest and/or other relationship with Endocare.
    • ,
  • Aaron Katz

      Affiliations

    • Financial interest and/or other relationship with Galil Medical.
    • ,
  • Louis Pisters

      Affiliations

    • Financial interest and/or other relationship with Endocare.
    • ,
  • Daniel Rukstalis
    • ,
  • Katsuto Shinohara
    • ,
  • J. Brantley Thrasher

References 

  1. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106
  2. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate- specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095
  3. Ball AJ, Gambill B, Fabrizio MD, Davis JW, Given RW, Lynch DF, et al. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. J Endourol. 2006;20:723
  4. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002;60:3
  5. Donnelly BJ, Saliken JC, Ernst DS, Ali-Ridha N, Brasher PM, Robinson JW, et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology. 2002;60:645
  6. Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology. 2001;57:518
  7. Cohen JK, Miller RJ, Ahmed S, Lutz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology. 2008;71:515
  8. Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology. 2002;60:12
  9. Benoit RM, Cohen JK, Miller RJ. Comparison of the hospital costs for radical prostatectomy and cryosurgical ablation of the prostate. Urology. 1998;52:820
  10. Prepelica KL, Okeke Z, Murphy A, Katz AE. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer. 2005;103:1625
  11. Ellis DS. Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. Urology. 2002;60:34
  12. Ellis DS, Manny TB, Rewcastle JC. Cryoablation as a primary treatment for localized prostate cancer followed by penile rehabilitation. Urology. 2007;69:306
  13. Cohen JK. Cryosurgery of the prostate: techniques and indications. Rev Urol. 2004;6:S20
  14. Rukstalis DB, Goldknopf JL, Crowley EM, Garcia FU. Prostate cryoablation: a scientific rationale for future modifications. Urology. 2002;60:19
  15. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the U.S. Preventive Services Task Force. Am J Prev Med. 2001;20:21
  16. Gage AA. History of cryosurgery. Semin Surg Oncol. 1998;14:99
  17. Cooper IS, Lee AS. Cryostatic congelation: a system for producing a limited, controlled region of cooling or freezing of biologic tissues. J Nerv Ment Dis. 1961;133:259
  18. Soanes WA, Gonder MJ, Shulman S. Apparatus and technique for cryosurgery of the prostate. J Urol. 1966;96:508
  19. Flocks RH, Nelson CM, Boatman DL. Perineal cryosurgery for prostatic carcinoma. J Urol. 1972;108:933
  20. Addonizio JC. Another look at cryoprostatectomy. Cryobiology. 1982;19:223
  21. Wieder J, Schmidt JD, Casola G, vanSonnenberg E, Stainken BF, Parsons CL. Transrectal ultrasound-guided transperineal cryoablation in the treatment of prostate carcinoma: preliminary results. J Urol. 1995;154:435
  22. Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72:1291
  23. Cohen JK, Miller RJ, Shuman BA. Urethral warming catheter for use during cryoablation of the prostate. Urology. 1995;45:861
  24. Onik G, Cooper C, Goldberg HI, Moss AA, Rubinsky B, Christianson M. Ultrasonic characteristics of frozen liver. Cryobiology. 1984;21:321
  25. Zisman A, Pantuck AJ, Cohen JK, Belldegrun AS. Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-guage brachytherapy template-technique and preliminary results. Urology. 2001;58:988
  26. Polascik TJ, Nosnik I, Mayes JM, Mouraviev V. Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology. 2007;70:117
  27. Siddiqui SA, Mynderse LA, Zincke H, Hoffmann NE, Lobo JR, Wilson TM. Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience. Urology. 2007;70:80
  28. Ghafar MA, Johnson CW, De La Taille A, Benson MC, Bagiella E, Fatal M, et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol. 2001;166:1333
  29. Baust JG, Gage AA, Klossner D, Clarke D, Miller R, Cohen J, et al. Issues critical to the successful application of cryosurgical ablation of the prostate. Technol Cancer Res Treat. 2007;6:97
  30. Gage AA, Baust JG. Cryosurgery of tumors. J Am Coll Surg. 2007;205:342
  31. Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology. 2002;60:40
  32. Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003;170:1126
  33. Mouraviev V, Evans B, Polascik TJ. Salvage prostate cryoablation after primary interstitial brachytherapy failure: a feasible approach. Prostate Cancer Prostatic Dis. 2006;9:99
  34. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998;37:171
  35. Larson TR, Robertson DW, Corica A, Bostwick DG. In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes. Urology. 2000;55:547
  36. Baust JG, Gage AA, Clarke D, Baust JM, Van Buskirk R. Cryosurgery – a putative approach to molecular-based optimization. Cryobiology. 2004;48:190
  37. Hollister WR, Mathew AJ, Baust JG, Van Buskirk RG. Effects of freezing on cell viability and mechanisms of cell death in a human prostate cancer cell line. Mol Urol. 1998;2:13
  38. Clarke DM, Baust JM, Van Buskirk RG, Baust JG. Addition of anticancer agents enhances freezing-induced prostate cancer cell death: implications of mitochondrial involvement. Cryobiology. 2004;49:45
  39. Clarke DM, Robilotto AT, VanBuskirk RG, Baust JG, Gage AA, Baust JM. Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007;10:175
  40. Rees J, Patel B, MacDonagh R, Persad R. Cryosurgery for prostate cancer. BJU Int. 2004;93:710
  41. Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int. 2005;95:1187
  42. Robilotto AT, Clarke D, Baust JM, Van Buskirk RG, Gage AA, Baust JG. Development of a tissue engineered human prostate tumor equivalent for use in the evaluation of cryoablative techniques. Technol Cancer Res Treat. 2007;6:81
  43. Clarke DM, Baust JM, Van Buskirk RG, Baust JG. Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer. Cryobiology. 2001;42:274
  44. Le Pivert P, Haddad RS, Aller A, Titus K, Doulat J, Renard M, et al. Ultrasound guided combined cryoablation and microencapsulated 5-fluorouracil inhibits growth of human prostate tumors in xenogenic mouse model assessed by luminescence imaging. Technol Cancer Res Treat. 2004;3:135
  45. Hanai A, Yang WL, Ravikumar TS. Induction of apoptosis in human colon carcinoma cells HT29 by sublethal cryo-injury: mediation by cytochrome C release. Int J Cancer. 2001;93:526
  46. Yang WL, Addona T, Nair DG, Qi L, Ravikumar TS. Apoptosis induced by cryo-injury in human colorectal cancer cells is associated with mitochrondrial dysfunction. Int Cancer. 2003;103:360
  47. Klossner DP, Robilotto AT, Clarke DM, Vanbuskirk RG, Baust JM, Gage AA, et al. Cryosurgical technique: assessment of the fundamental variables using human prostate cancer model systems. Cryobiology. 2007;55:189
  48. Chao BH, He X, Bischof JC. Pre-treatment inflammation induced by TNF-alpha augments cryosurgical injury on human prostate cancer. Cryobiology. 2004;49:10
  49. Klossner DP, Baust JM, VanBuskirk RG, Gage AA, Baust JG. Cryoablative response of prostate cancer cells is influenced by androgen receptor expression. BJU Int. 2008;101:1310
  50. Shinohara K, Connolly JA, Presti JC, Carroll PR. Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. J Urol. 1996;156:115
  51. Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997;157:921
  52. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nonograms (Partin Tables) for the new millennium. Urology. 2001;58:843
  53. Naya Y, Babaian RJ. The predictors of pelvic lymph node metastasis as radical retropubic prostatectomy. J Urol. 2003;170:2306
  54. Long JP. Is there a role for cryoablation of the prostate in the management of localized prostate carcinoma?. Hematol Oncol Clin North Am. 1996;10:675
  55. Bahn DK, Lee F, Silverman P, Bahn E, Badalament R, Kumar A, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer. 2003;2:111
  56. Shinohara K, Rhee B, Presti JC, Carroll PR. Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol. 1997;158:2206
  57. Benoit RM, Cohen JK, Miller RJ. Cryosurgery for prostate cancer: new technology and indications. Cur Urol Rep. 2000;1:41
  58. Scardino PT, Frankel JM, Wheeler TM, Meacham RB, Hoffman GS, Seale C, et al. The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol. 1986;135:510
  59. De La Taille A, Benson MC, Bagiella E, Burchardt M, Shabsigh A, Olsson CA, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int. 2000;85:281
  60. Mouraviev V, Polascik TJ. Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol. 2006;16:152
  61. Wake RW, Hollabaugh RS, Bond KH. Cryosurgical ablation of the prostate for localized adenocarcinoma: a preliminary experience. J Urol. 1996;155:1678
  62. Badalament RA, Bahn DK, Kim H, Kumar A, Bahn JM, Lee F. Patient-reported complications after cryoblation therapy for prostate cancer. Urology. 1999;54:295
  63. Bahn DK, Lee F, Solomon MH, Gontina H, Klionsky DL, Lee FT. Prostate cancer: US-guided percutaneous cryoablation (Work in progress). Radiology. 1995;194:551
  64. Robinson JW, Saliken JC, Donnelly BJ, Barnes P, Guyn L. Quality-of-life outcomes for men treated with cryosurgery for localized prostate carcinoma. Cancer. 1999;86:1793
  65. Crook JM, Perry GA, Robertson S, Esche BA. Routine biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology. 1995;45:624
  66. Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol. 2001;165:1937
  67. Donnelly BJ, Saliken JC, Ernst DS, Weber B, Robinson JW, Brasher PM, et al. Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. Prostate Cancer Prostatic Dis. 2005;8:235
  68. Ismail M, Ahmed S, Kastner C, Davis J. Salvage cryotherapy for recurrent cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007;100:760
  69. Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys. 2003;56:448
  70. Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 2002;168:2001
  71. Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer. 2006;107:275
  72. Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, Sandler HM. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 1997;38:941
  73. Crook JM, Bahadur YA, Robertson SJ, Perry GA, Esche BA. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer. 1997;79:81
  74. Gheiler EL, Tefilli MV, Tiguert R, Grignon D, Cher ML, Sakr W, et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 1998;51:789
  75. Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995;153:104
  76. Moul JW, Paulson DF. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer. 1991;68:1265
  77. Pontes JE, Montie J, Klein E, Huben R. Salvage surgery for radiation failure in prostate cancer. Cancer. 1993;71:976
  78. Lerner SE, Blute ML, Zincke H. Critical evaluation of salvage surgery for radio recurrent/resistant prostate cancer. J Urol. 1995;154:1103
  79. Ng CK, Moussa M, Downey DB, Chin JL. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol. 2007;178:1253
  80. Nguyen PL, D'amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110:1417
  81. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy (Patterns of recurrence and cancer control). Urol Clin North Am. 1997;24:395
  82. Bales GT, Williams MJ, Sinner M, Thisted RA, Chodak GW. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology. 1995;46:676
  83. Cespedes RD, Pisters LL, von Eschenbach AC, McGuire EJ. Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. J Urol. 1997;157:237
  84. de la Taille A, Hayek O, Benson MC, Bagiella E, Olsson CA, Fatal M, et al. Salvage cryotherapy for recurrent prosate cancer after radiation treatment: the Columbia experience. Urology. 2000;55:79
  85. De La Taille A, Benson MC, Bagiella E, Burchardt M, Shabsigh A, Olsson CA, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int. 2000;85:281
  86. Cresswell J, Asterling S, Chaudhary M, Sheikh N, Greene D. Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease. BJU Int. 2006;97:969
  87. Han KR, Belldegrun AS. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int. 2004;93:14
  88. Katz AE, Prepelica KL, Masson P, Benson MC, McKiernan JM. Salvage cryosurgical ablation of the prostate (TCAP) for patients failing radiation: 10-year experience. J Urol. 2005;173:450;(abstract 1662)
  89. Robinson JW, Donnelly BJ, Coupland K, Siever JE, Saliken JC, Scott C, et al. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urol Oncol. 2006;24:472
  90. Anastasiadis AG, Sachdev R, Salomon L, Ghafar MA, Stisser BC, Shabsigh R, et al. Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. J Cancer Res Clin Oncol. 2003;129:676
  91. Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol. 1999;161:857
  92. Stephenson AJ, Scardino PT, Bianco FJ, DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol. 2004;172:2239
  93. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. “Male lumpectomy”: focal therapy for prostate cancer using cryoablation. Urology. 2007;70:16

 This document is being reprinted as submitted without editorial or independent peer review. This report is also available at http://www.auanet.org/guidelines/.

 Requests for reprints: Guidelines Department, American Urological Association, 1000 Corporate Blvd., Linthicum, Maryland 21090.

 See Editorial on page 1882.

 Editor's Note: This article is the first of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2266 and 2267.

PII: S0022-5347(08)02017-X

doi: 10.1016/j.juro.2008.07.108

The Journal of Urology
Volume 180, Issue 5 , Pages 1993-2004 , November 2008

Article Tools